Department of Radiotherapy, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai 264000, Shandong, China.
Department of Thoracic Surgery, Yantai Yuhuangding Hospital, The Affiliated Hospital of Qingdao University, Yantai 264000, Shandong, China.
Aging (Albany NY). 2020 Apr 24;12(8):7465-7479. doi: 10.18632/aging.103094.
We investigated the prognostic significance of () single nucleotide polymorphisms (SNPs) in 720 Han Chinese non-small cell lung cancer (NSCLC) patients who underwent radiation or chemoradiation therapy. Kaplan-Meier survival curves showed that overall survival (OS) and disease-free survival (DFS) rates were significantly associated with two SNPs, rs664143 and rs189037. Patients with the rs664143 GA or AA genotype had poorer DFS (hazard ratio (HR) = 1.40, 95% confidence interval (CI) = 1.05-1.86, = 0.021) and OS (HR = 1.28, 95%CI = 1.12-1.78, = 0.040) than those with the rs664143 GG phenotype. Patients with the rs189037 AG/GG genotypes had poorer prognoses than those with the rs189037 AA genotype (AG/GG AA: DFS, HR = 1.44, 95%CI = 1.06-1.95, =0.019; OS, HR = 1.16, 95%CI = 1.16-1.17-2.21, =0.004). These results were confirmed by subgroup analysis based on clinical factors such as smoking, histology, tumor stage, treatment, and radiation dose, all of which were significantly associated with DFS and OS rates in NSCLC patients. These findings show that rs664143 and rs189037 variants determine prognosis in NSCLC patients that have undergone radiation or chemoradiation therapies.
我们研究了 720 名接受放疗或放化疗的汉族非小细胞肺癌(NSCLC)患者中 () 单核苷酸多态性(SNP)的预后意义。Kaplan-Meier 生存曲线显示,总生存(OS)和无病生存(DFS)率与两个 SNP 显著相关,rs664143 和 rs189037。rs664143 GA 或 AA 基因型患者的 DFS(风险比(HR)=1.40,95%置信区间(CI)=1.05-1.86,=0.021)和 OS(HR = 1.28,95%CI = 1.12-1.78,=0.040)明显差于 rs664143 GG 表型患者。rs189037 AG/GG 基因型患者的预后明显差于 rs189037 AA 基因型患者(AG/GG AA:DFS,HR = 1.44,95%CI = 1.06-1.95,=0.019;OS,HR = 1.16,95%CI = 1.16-1.17-2.21,=0.004)。这些结果通过基于吸烟、组织学、肿瘤分期、治疗和放疗剂量等临床因素的亚组分析得到了证实,这些因素均与 NSCLC 患者的 DFS 和 OS 率显著相关。这些发现表明,rs664143 和 rs189037 变异决定了接受放疗或放化疗的 NSCLC 患者的预后。